Therapeutic options for patients with myeloma have radically changed over the
past ten years. Beginning with the advances in therapy resulting from the use of
high dose therapy and autologous bone marrow or stem cell transplant, we have
more than doubled the median survival for patients as a whole, and have now a
wealth of different biology based treatment approaches for our patients in all
disease stages. The purpose of this book is to update the various treatment
options for patients with myeloma, as well as to focus on the emerging and
speculative aspects of myeloma therapy. This will require review of basic
mechanisms of disease as